Dyslipidemia refers to abnormalities in lipids and lipoproteins in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease. The most common lipid abnormalities include elevated levels of LDL-cholesterol and/or triglyceride levels. Statins are firmly established as first-line treatment for most patients with dyslipidemia, owing to their proven CV benefits, physician familiarity with the class, and the increased availability of low-priced generic options. However, a lack of high-quality CV outcomes trial data has weakened physicians’ confidence in many nonstatin drug classes, particularly those agents that lower triglyceride levels. Nonetheless, physicians recognize that many statin-treated patients have residual CV risk and consequently use additional therapies, including the efficacious but expensive proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. This report explores the current EU5 prescribing landscape for dyslipidemia and the factors that influence it.

Questions Answered

  • Do physicians have a preference for Praluent or Repatha? What are the major factors driving/constraining use of the PCSK9 inhibitor class?
  • How do drug preferences change at each line of therapy in different geographies?
  • What is influencing the prescribing of endocrinologists and cardiologists for dyslipidemia, and how are these factors expected to change?
  • How do prescribing patterns differ between lipid disorders; which therapies are most popular for the treatment of these different populations?

Product Description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that clients can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.

Geographies:France, Germany, Italy, Spain, and the United Kingdom.

Primary research:128 cardiologists and 128 endocrinologists, with 51 respondents in France, 50 in Germany, 51 in Italy, 53 in Spain, and 51 in the United Kingdom.

Key drugs covered: Repatha (evolocumab), Praluent (alirocumab), statins, fibrates, ezetimibe (Zetia, generics), prescription omega-3 fatty acid compounds.

Table of contents

  • Dyslipidemia - Current Treatment - Detailed, Expanded Analysis: Physician Insights (EU5)

Author(s): Andrew Frost

Andrew Frost is a Business Insights Analyst in Decision Resources Group’s Cardiovascular, Metabolic, Renal, and Hematologic Disorders team focusing on obesity and non-alcoholic steatohepatitis (NASH). In this role, he evaluates the latest primary and secondary research, as well as available commercial information, to forecast the potential of developmental drugs and provide insight on the various dynamics affecting relevant markets. Prior to joining DRG, Andrew worked as a Senior Drug Analyst at Citeline in the Cardiovascular and Metabolic Team. Andrew holds a BSc (Hons) degree in Pharmacology, awarded by King’s College London, and he has previously worked in the Immunopharmacology team at UCB.


Related Reports

Dyslipidemia - Landscape & Forecast - Disease Landscape & Forecast

Dyslipidemia is a key modifiable risk factor for cardiovascular disease (CVD). Current lipid-modifying therapies, including statins, ezetimibe, bempedoic...

View Details

Dyslipidemia - Current Treatment - Detailed, Expanded Analysis: Physician Insights (US) : Hypertriglyceridemia

Hypertriglyceridemia refers to abnormalities in the concentration of triglycerides in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease and, with very high levels,...

View Details